XML 43 R26.htm IDEA: XBRL DOCUMENT
v3.25.4

Common Stock, Stock Options, Restricted Stock Awards, and Warrants (Tables) | 12 Months Ended
--- | ---
Sep. 30, 2025
Common Stock, Stock Options, Restricted Stock Awards, and Warrants [Abstract] |
Schedule of Assumptions were used in determining the Fair Value of Stock Option | The following assumptions were used in determining the fair value of stock option grants for the years ended September 30, 2025 and 2024:
|  | 2025 |  | 2024
Risk-free interest rate |  | 4.17 – 4.31% |  | 4.62 – 4.66%
Expected dividend yield |  | 0.00% |  | 0.00%
Expected term |  | 5.50 – 10 years |  | 5.50 – 10 years
Expected volatility |  | 85% |  | 85 – 86%
The following assumptions were used in determining the fair value of the Citius Oncology stock option grants for the year ended September 30, 2025 and 2024:
|  | 2025 |  | 2024
Risk-free interest rate |  | 4.08-4.18% |  | 4.66%
Expected dividend yield |  | 0.00 |  | 0.00%
Expected term |  | 5.50-6.50 years |  | 6.50 years
Expected volatility |  | 85% |  | 87%
Schedule of Option Activity Under Our Stock Option Plans | A summary of option activity under our plans (excluding the NoveCite and Citius Oncology Stock Plans) is presented below:
|  | Option Shares |  |  | Weighted- Average Exercise Price |  |  | Weighted- Average Remaining Contractual Term |  | Aggregate Intrinsic Value |
Outstanding at September 30, 2024 |  |  | 656,084 |  |  | $ | 36.41 |  |  | 7.26 years |  | $ | 0.00 |
Granted |  |  | 185,000 |  |  | $ | 9.50 |  |  |  |  |  |  |
Exercised |  |  | — |  |  |  |  |  |  |  |  |  |  |
Forfeited or expired |  |  | (1,574 | ) |  | $ | 242.80 |  |  |  |  |  |  |
Outstanding at September 30, 2025 |  |  | 839,510 |  |  | $ | 30.09 |  |  | 6.90 years |  | $ | 0.00 |
Exercisable at September 30, 2025 |  |  | 512,509 |  |  | $ | 39.70 |  |  | 5.88 years |  | $ | 0.00 |
A summary of option activity under the Citius Oncology plan is presented below:
|  | Shares |  |  | Weighted- Average Exercise Price |  |  | Weighted- Average Remaining Contractual Term |  | Aggregate Intrinsic Value |
Outstanding at September 30, 2024 |  |  | 12,750,000 |  |  | $ | 2.15 |  |  | 8.78 years |  | $ | — |
Granted |  |  | 5,750,000 |  |  |  | 1.07 |  |  |  |  |  |  |
Forfeited |  |  | (400,000 | ) |  |  |  |  |  |  |  |  |  |
Outstanding at September 30, 2025 |  |  | 18,100,000 |  |  | $ | 1.83 |  |  | 8.21 years |  | $ | 5,386,000 |
Exercisable at September 30, 2025 |  |  | 9,781,250 |  |  | $ | 2.02 |  |  | 7.94 years |  | $ | 1,136,500 |
Schedule of Exercise of Outstanding Warrants | The following table summarizes the warrants outstanding at September 30, 2025:
|  | Exercise price |  |  | Number |  |  | Expiration Dates
August 2018 Offering Investors |  |  | 28.75 |  |  |  | 156,863 |  |  | August 14, 2026
August 2018 Offering Agent |  |  | 39.84 |  |  |  | 7,576 |  |  | August 8, 2026
September 2019 Offering Investors |  |  | 19.25 |  |  |  | 111,732 |  |  | September 27, 2026
September 2019 Offering Underwriter |  |  | 27.97 |  |  |  | 7,774 |  |  | September 27, 2026
May 2020 Offering Investors |  |  | 25.00 |  |  |  | 66,824 |  |  | November 18, 2025
January 2021 Offering Investors |  |  | 30.78 |  |  |  | 123,648 |  |  | July 27, 2026
January 2021 Offering Agent |  |  | 40.44 |  |  |  | 14,065 |  |  | July 27, 2026
February 2021 Offering Investors |  |  | 42.50 |  |  |  | 823,211 |  |  | February 19, 2026
February 2021 Offering Agent |  |  | 47.03 |  |  |  | 100,256 |  |  | February 19, 2026
May 2023 Offering Investors |  |  | 37.50 |  |  |  | 500,000 |  |  | May 8, 2028
May 2023 Offering Agent |  |  | 37.50 |  |  |  | 35,000 |  |  | May 3, 2028
April 2024 Offering Investors |  |  | 18.75 |  |  |  | 857,143 |  |  | October 30, 2029
April 2024 Offering Agent |  |  | 21.875 |  |  |  | 60,000 |  |  | April 25, 2029
November 2024 Offering Investors |  |  | 6.25 |  |  |  | 480,000 |  |  | November 18, 2029
November 2024 Offering Agent |  |  | 7.8125 |  |  |  | 33,600 |  |  | November 15, 2029
January 2025 Offering Investors |  |  | 3.91 |  |  |  | 743,496 |  |  | January 8, 2030
January 2025 Offering Agent |  |  | 5.0438 |  |  |  | 52,045 |  |  | January 7, 2030
April 2025 Offering Agent |  |  | 1.4375 |  |  |  | 121,739 |  |  | April 1, 2030
June 2025 Offering Investor |  |  | 1.00 |  |  |  | 9,840,000 |  |  | June 11, 2027
June 2025 Offering Agent |  |  | 1.525 |  |  |  | 344,400 |  |  | June 11, 2027
|  |  |  |  |  |  | 14,479,372 |  |  |
The following table summarizes the warrants outstanding at September 30, 2025:
|  | Exercise price |  |  | Number |  |  | Expiration Dates
July 2025 Offering Investors |  | $ | 1.32 |  |  |  | 6,818,182 |  |  | July 17, 2030
July 2025 Offering Agent |  |  | 1.65 |  |  |  | 272,727 |  |  | July 17, 2030
July 2025 Prior Offering Agent |  |  | 1.65 |  |  |  | 477,273 |  |  | July 17, 2030
September 2025 Offering Investors |  |  | 1.84 |  |  |  | 5,142,858 |  |  | March 10, 2031
September 2025 Offering Agent |  |  | 1.92 |  |  |  | 205,714 |  |  | March 10, 2031
September 2025 Prior Offering Agent |  |  | 2.1875 |  |  |  | 360,000 |  |  | March 10, 2031
|  |  |  |  |  |  | 13,276,754 |  |  |
Schedule of Common Stock Reserved for Future Issuances | A summary of common stock reserved for future issuances by Citius Pharma excluding our subsidiaries as of September 30, 2025 is as follows:
Stock plan options outstanding |  |  | 839,510 |
Stock plan shares available for future grants |  |  | 118,000 |
Warrants outstanding |  |  | 14,479,372 |
Total |  |  | 15,436,882 |
A summary of common stock reserved for future issuances by Citius Oncology as of September 30, 2025 is as follows:
Stock plan options outstanding |  |  | 18,100,000 |
Restricted stock awards |  |  | 11,600,000 |
Stock plan shares available for future grants |  |  | 300,000 |
Warrants outstanding |  |  | 13,276,754 |
Total |  |  | 43,276,754 |

X
- Definition Tabular disclosure of the change in common stock outstanding. + References No definition available. + Details
Name: | us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration